鹭燕医药 (002788.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

18.6x

Market Cap

CNY 4.10B

MomentumView details →

1D Return

−3.30%

YTD Return

−48.25%

RSI (14)

49.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

18.6x

Market Cap

CNY 4.10B

RSI (14)

49.5

MomentumView details →

1D Return

−3.30%

YTD Return

−48.25%

ProfitabilityView details →

Gross Margin

7.00%

Net Margin

1.30%

EBITDA Margin

2.17%

ROE (TTM)

8.22%

ROA (TTM)

2.08%

Asset Turnover

1.60x

GrowthView details →

Revenue YoY

+4.46%

EPS YoY

−16.66%

FCF YoY

+3.46%

Revenue CAGR 3Y

+2.97%

EPS CAGR 3Y

−6.82%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.46x

Current Ratio

1.11x

Quick Ratio

0.80x

Div Yield

3.19%

Div Rate

CNY 0.35

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

21.42B

Net Income (TTM)

277.50M

Op. CF (TTM)

519.76M

Latest newsMore news →

Luyan Pharmaceutical announced its first-half 2026 results: revenue of 10.583 billion yuan, up 1.75% year-on-year; net profit attributable to shareholders of 143 million yuan, down 7.46% year-on-year; non-GAAP net profit of 138 million yuan, down 9.88% year-on-year.19d ago

Similar companies

国科恒泰301370.SZ 浙农股份002758.SZ 远大控股000626.SZ ST海王000078.SZ 广聚能源000096.SZ 吉峰科技300022.SZ Find similar companies →

Latest newsMore news →

Luyan Pharmaceutical announced its first-half 2026 results: revenue of 10.583 billion yuan, up 1.75% year-on-year; net profit attributable to shareholders of 143 million yuan, down 7.46% year-on-year; non-GAAP net profit of 138 million yuan, down 9.88% year-on-year.19d ago